February 27, 2018
ProLung, Inc., the world leader in innovative predictive analytics technology and non-invasive tests for the risk stratification of lung cancer, announced today that Neil Berkley has joined the Company's Board of Directors.
November 28, 2017
ProLung, Inc., the world leader in accurate, non-invasive, and radiation-free predictive analytics for rapid risk stratification of lung cancer, is pleased to share the PharmaVOICE “2018 Year in Preview: Treatment to Wellness” featuring ProLung president and CEO, Steven C. Eror.
September 14, 2017
ProLung, Inc. and Steven C. Eror, President and CEO, were honored at the prestigious Swedish American Life Science Summit (SALSS) meeting in August 2017 as a “Rising Star.” ProLung was further highlighted by Forbes.com ! It’s very exciting to be recognized for our mission to make a difference
May 11, 2017
Salt Lake City, UT, May 11, 2017 — ProLung, Inc., the leader in innovative predictive analytics technology and non-invasive tests for the risk stratification of lung cancer, announced today the successful closing of its private placement. The private offering was expected to raise $5.2
May 04, 2017
Salt Lake City, UT, May 4, 2017 — ProLung, Inc. , a leader in innovative predictive analytics technology and non-invasive biomarkers for the risk stratification of lung cancer, announced today it has been selected to present at the upcoming Cavendish Global Health Impact Forum
February 16, 2017
Salt Lake City, Utah, February 16, 2017 – ProLung, a predictive analytics and risk stratification company that has developed a novel, cost effective, and non-invasive test to identify cancerous and noncancerous lung nodules, announced today that Robin L.
December 10, 2016
Steven C. Eror , President and CEO of ProLung, meets with Gregory C. Simon , White House Cancer Moonshot Task Force, Executive Director in the Office of the Vice President.
November 02, 2016
ProLungDX seeks funds for cancer test; sees eventual IPO – CEO Proprietary Intelligence ProLungDX , a maker of lung cancer detection devices, is looking to raise USD 5.25m from high net worth investors for US commercial development in advance of an expected initial public offering or trade sale,
October 13, 2016
Salt Lake City, UT, USA, October 13, 2016 – ProLungdx™ today announced plans to present its leading-edge innovation for patients at risk of lung cancer during the 2016 BIO Investor Forum in San Francisco, California October 18 and 19, 2016. For the first time in an international biotech